CompanyBYSINasdaqFlorham Park, NJ

BeyondSpring Pharmaceuticals Inc.

BeyondSpring develops Plinabulin, a GEF-H1 agonist in late-stage development for multiple cancer indications.

SEC EDGAR ClinicalTrials.gov beyondspringpharma.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

BeyondSpring gets FDA Fast Track for plinabulin, sells China unit stake to fund trial

Sep 29Regulatory milestoneBeyondSpring Pharmaceuticals Inc.

BeyondSpring files $11.9 million at-the-market offering with Citizens

Sep 29FinancingBeyondSpring Pharmaceuticals Inc.

August 2026

BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 results

Aug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.

June 2026

BeyondSpring discloses finalized pay package for new CEO Min Qiu

Jun 29PeopleBeyondSpring Pharmaceuticals Inc.